Agents that target NaV1.8, a voltage-gated sodium channel, are showing promise. The FDA approved one of them, Journavx ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports Q1 earnings with $4.32 EPS and $2.85B revenue. Stock up 25.48% in past year, ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its ...

The new campaign stars former NFL quarterback Alex Smith, whose leg injury during a 2018 game led to a case of ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% ...

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

Despite the earnings miss, Vertex raised the low end of its full-year 2025 revenue guidance to $11.85-$12 billion, compared ...

Nearly every investor has heard the adage, "Sell in May and go away." The premise is that stock market returns are often ...

Broadcom's stock has seen a dramatic decline of almost 22% from its recent high in December 2024, driven by escalating market fears due to trade wars between the U.S. and China. Yet, the stock remains ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...